| CAS NO: | 554-57-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 25g | 电议 |
| Molecular Weight (MW) | 236.27 |
|---|---|
| Formula | C5H8N4O3S2 |
| CAS No. | 554-57-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 47 mg/mL (198.9 mM) |
| Water: < 1 mg/mL | |
| Ethanol: 3 mg/mL (12.7 mM) | |
| SMILES | CC(/N=C1SC(S(=O)(N)=O)=NN/1C)=O |
| Synonyms | Methenamide; Neptazaneat; Naptazane; CL 8490; Methazolamide; Neptazane; N Methylacetazolamide;N-Methylacetazolamide; CL8490; CL-8490 |
| In Vitro | In vitro activity: Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively. Methazolamide is of strength equal to acetazolamide, another carbonic anhydrase inhibitor used to treat irregular breathing disorders. However, methazolamide differs from acetazolamide in that it fails to activate Ca2+-dependent potassium channels in skeletal muscles. Kinase Assay: Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively. |
|---|---|
| In Vivo | Methazolamide does not impair respiratory work performance in anesthetized rabbits. |
| Animal model | Rabbits |
| Formulation & Dosage | N/A |
| References | Bioorg Med Chem Lett. 2003 Mar 10;13(5):841-5; Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R648-54. |
m.cnreagent.com